Edaravone in the Treatment of Optic Neuritis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
• Patients with a first episode of optic neuritis in either eye
• First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone
Locations
Other Locations
China
Yi Du
RECRUITING
Nanning
Time Frame
Start Date: 2022-01-15
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 50
Treatments
Experimental: Edaravone
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Guangxi Medical University